CAR-T cells offer a lasting benefit through a single treatment, sparing patients with high-risk conditions from the toxicity associated with salvage chemotherapy and autologous transplants. These approvals have changed the standard of care for patients who are either resistant to initial treatment or experience early recurrence after first-line therapy.
As per DelveInsight’s estimates, in 2023, the total eligible cases of NHL for CAR-T were around 126K in the 7MM. In 2023, the total NHL incident cases in selected subtypes were around 17K cases in Germany. DLBCL stands out as the most prevalent subtype among selected types of non-Hodgkin lymphoma in EU4 and UK, with...
